Literature DB >> 16527839

Homologous and lysophosphatidic acid-induced desensitization of the atrial natriuretic peptide receptor, guanylyl cyclase-A, in MA-10 leydig cells.

Dieter Müller1, Lourdes Cortes-Dericks, Lygia T Budnik, Bärbel Brunswig-Spickenheier, Maria Pancratius, Robert C Speth, Amal K Mukhopadhyay, Ralf Middendorff.   

Abstract

The cardiac hormone atrial natriuretic peptide (ANP) signals via interaction with a plasma membrane receptor, which has guanylyl cyclase (GC) activity and is referred to as GC-A. Desensitization of GC-A is thought to represent a physiologically important regulatory mechanism, but the signaling pathways implicated and cell type-specific effects are still poorly understood. Here we demonstrate that sustained exposure to either ANP itself or the bioactive lipid lysophosphatidic acid (LPA) elicits GC-A desensitization in MA-10 Leydig cells. Both reactions show similar kinetics and evoke equal decreases (by 40%) in GC-A hormone responsiveness. Homologous (ANP induced) desensitization, in which cGMP is generated as second messenger, is blocked by distinct cAMP-dependent protein kinase [protein kinase A (PKA)] inhibitors, H 89, and Rp-8-CPT-cAMPs, providing evidence that PKA mediates the reaction. Accordingly, the ANP/cGMP-elicited effects are mimicked by a cAMP analog, 8-bromo-cAMP. The LPA-induced (heterologous) desensitization is not blocked by PKA inhibition, indicating a different signaling pathway. LPA, but not ANP, enhances ERK phosphorylation and induces cell rounding together with a dramatic reorganization of actin filaments. Consistent with the identification of LPA receptor (LPA2 and LPA3) gene expression, the findings are indicative of LPA receptor-mediated reactions. This study demonstrates for the first time coexistence of homologous and heterologous desensitization of GC-A in the same cell type, reveals that these reactions are mediated by different pathways, and identifies a novel cross talk between phospholipid and natriuretic peptide signaling. The morphoregulatory activities exerted by LPA suggest a crucial role for Leydig cell physiology.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16527839     DOI: 10.1210/en.2006-0092

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

Review 1.  Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases.

Authors:  Lincoln R Potter
Journal:  Pharmacol Ther       Date:  2010-12-24       Impact factor: 12.310

2.  A Glutamate-Substituted Mutant Mimics the Phosphorylated and Active Form of Guanylyl Cyclase-A.

Authors:  Neil M Otto; William G McDowell; Deborah M Dickey; Lincoln R Potter
Journal:  Mol Pharmacol       Date:  2017-04-17       Impact factor: 4.436

3.  Homologous desensitization of guanylyl cyclase A, the receptor for atrial natriuretic peptide, is associated with a complex phosphorylation pattern.

Authors:  Juliane Schröter; René P Zahedi; Michael Hartmann; Birgit Gassner; Alexandra Gazinski; Jens Waschke; Albert Sickmann; Michaela Kuhn
Journal:  FEBS J       Date:  2010-04-26       Impact factor: 5.542

4.  A functional screen provides evidence for a conserved, regulatory, juxtamembrane phosphorylation site in guanylyl cyclase a and B.

Authors:  Andrea R Yoder; Jerid W Robinson; Deborah M Dickey; Joshua Andersland; Beth A Rose; Matthew D Stone; Timothy J Griffin; Lincoln R Potter
Journal:  PLoS One       Date:  2012-05-09       Impact factor: 3.240

5.  Homologous and heterologous desensitization of guanylyl cyclase-B signaling in GH3 somatolactotropes.

Authors:  Iain R Thompson; Samantha M Mirczuk; Lorna Smith; Andrew J Lessey; Bigboy Simbi; Andrew Sunters; Gary F Baxter; Victoria J Lipscomb; Imelda M McGonnell; Caroline P Wheeler-Jones; Abir Mukherjee; Mark S Roberson; Craig A McArdle; Robert C Fowkes
Journal:  Cell Tissue Res       Date:  2013-12-20       Impact factor: 5.249

6.  Skeletal muscle alterations in tachycardia-induced heart failure are linked to deficient natriuretic peptide signalling and are attenuated by RAS-/NEP-inhibition.

Authors:  Alexander Dietl; Ingrid Winkel; Gabriela Pietrzyk; Michael Paulus; Astrid Bruckmann; Josef A Schröder; Samuel Sossalla; Andreas Luchner; Lars S Maier; Christoph Birner
Journal:  PLoS One       Date:  2019-12-04       Impact factor: 3.240

Review 7.  Targeting Lysophosphatidic Acid in Cancer: The Issues in Moving from Bench to Bedside.

Authors:  Yan Xu
Journal:  Cancers (Basel)       Date:  2019-10-10       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.